New Health Ministry Of Chile Reaffirms Path To Compulsory Licence For Hepatitis C Drugs 04/09/2018 by Intellectual Property Watch Leave a Comment Last week, Chilean Health Minister Emilio Santelices, appointed by President Piñera – who took office this year – rejected an attempt from company Gilead and a Big Pharma-related association of international drug makers in Chile to put down the resolution 399/2018 declaring public health justifications for the issuing of compulsory licences for sofosbuvir to treat a hepatitis C epidemic in Chile, that was issued by the previous government of Michele Bachelet, writes Luis Villarroel.
African Health Ministers Approve Roadmap For Medicines Access, Framework To End Cholera 03/09/2018 by Catherine Saez, Intellectual Property Watch 1 Comment Health ministers from the World Health Organization Africa region last week endorsed a roadmap for access for the years 2019-2023 concerning areas such as fair pricing, intellectual property management, and supply chain management. The previous day, they pledged to implement key strategies to end cholera outbreaks in the African region by 2030.
UN Tuberculosis Negotiations: What Is At Stake? 30/08/2018 by David Branigan, Intellectual Property Watch 2 Comments With negotiations over the final language of a United Nations high level declaration on ending tuberculosis still ongoing, the stakes are high as different TB stakeholders await the outcome. The language in question could either raise or reduce barriers to affordable access to life-saving TB drugs, according to civil society groups.
Indonesia, Cuba Do Not Appeal WTO Plain-Packaging Ruling 27/08/2018 by William New, Intellectual Property Watch 4 Comments The governments of Cuba and Indonesia today chose not to appeal a June ruling at the World Trade Organization that upheld Australia’s law requiring tobacco products sold in the country to be packaged without logos or other trademarked designs. That leaves Honduras and the Dominican Republic alone in their appeals of the decision.
New Dutch Foundation To Address High Medicines Pricing Announces Plan To File Complaint With Competition Authority 27/08/2018 by Intellectual Property Watch 1 Comment The newly established Dutch Pharmaceutical Accountability Foundation has announced its first action to address unreasonably high medicines prices in the Netherlands. The Foundation will request the Netherlands Authority for Consumers and Markets to look into the price hike for the medicine chenodeoxycholic acid (CDCA) by the company Leadiant Biosciences Ltd (formerly Sigma-Tau). CDCA is used for the treatment of children and adults with cerebrotendinous xanthomatosis (CTX), a rare genetic metabolic disease that affects around 60 people in the Netherlands.
Negotiators On UN TB Resolution May Have A Deal 23/08/2018 by William New and David Branigan, Intellectual Property Watch 23 Comments NEW YORK – Negotiators for a United Nations declaration on tuberculosis, meeting intensively in New York this week, may have reached agreement today on a key sticking point related to intellectual property, innovation and access to new medicines, according to sources. An agreement, if accepted by other delegations, could allow the text to proceed to the high-profile High-Level Meeting scheduled to take place at the UN General Assembly next month.
Can A Surge In Activism Defeat American Big Pharma? 22/08/2018 by Guest contributor for Intellectual Property Watch Leave a Comment By Vinayak Bhardwaj – Not a day passes in America without news of a drug company raising prices on prescription drugs. Americans pay two to six times more for prescription drugs than those living in other developed countries, who earn the same income.
Civil Society And TRIPS Flexibilities Series – Translations Now Available 20/08/2018 by Intellectual Property Watch, Intellectual Property Watch Leave a Comment Patients around the world, in developing and developed countries, are encountering barriers to access to affordable medical products, in part due to patents and resulting high prices. This is occurring despite longstanding protections built into international trade rules to allow smaller economies to act on behalf of their people and make such medical products available regardless of patents. These protections are often referred to as flexibilities in the 1994 World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The prevailing view is that knowledge, understanding and use of them remains limited among policymakers and many potential beneficiaries, even as patent-strong nations and their industries work to narrow the reach and ability to use these flexibilities. In the face of this, global civil society in recent years have increasingly begun work to change the direction of this trend, with the ultimate goal of helping people everywhere – but particularly poor populations – obtain drugs they need that exist but are out of their reach. Now, the series of Intellectual Property Watch stories on this subject sponsored by Make Medicines Affordable have been translated into five languages.
A Look At Honduras’ Appeal In WTO Ruling On Tobacco Plain Packaging 03/08/2018 by David Branigan, Intellectual Property Watch 3 Comments In an appeal of a recent World Trade Organization dispute panel ruling, Honduras detailed a list of alternate interpretations of the decision to uphold Australia’s tobacco plain packaging measures. Honduras called on the WTO Appellate Body to “reverse the Panel’s findings and conclusions,” claiming that the ruling was “not the result of an objective assessment of the matter.”
Report – Patent Abuse A Leading Cause Of High Drug Prices In US 03/08/2018 by Intellectual Property Watch 1 Comment Pharmaceutical companies have created an “untenable” situation by engaging in exploitative patenting practices to extend monopolies, increasing drug prices and delaying competition from more affordable generics, according to a new NGO report analysing drug prices.